8 research outputs found

    Cox proportional hazards analysis for time to first safety-related dose reductions or discontinuations in patients treated for 24 or 48 weeks with peginterferon alfa-2a or alfa-2b and ribavirin.

    No full text
    <p>(A) All treatment-naive patients (G1–6) assigned to 24 or 48 weeks of treatment with peginterferon alfa-2a or alfa-2b/RBV (N = 3181); (B) Subgroup 2: treatment-naive Caucasian, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon alfa-2a/RBV (n = 951).</p

    Scoring system used to identify patients in subgroup 2<sup>a</sup> with a high or low probability of achieving SVR24.

    No full text
    <p>Scoring system used to identify patients in subgroup 2<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0151703#t001fn001" target="_blank"><sup>a</sup></a> with a high or low probability of achieving SVR24.</p

    Enrollment and patient disposition.

    No full text
    <p><sup>a</sup>Other reasons (more than one reason may apply to a given patient): no final confirmation from the investigator (n = 56); contraindications to therapy (n = 15); HCV RNA-negative at screening/baseline (n = 12); end-stage renal disease (n = 7); major organ transplantation (n = 2); not treated with peginterferon alfa (n = 1) or ribavirin (n = 2); acute hepatitis C (n = 1); co-infection with HIV (n = 115); co-infection with HBV (n = 74); treatment with regimen other than peginterferon alfa-2a/ribavirin or peginterferon alfa-2b/ribavirin (n = 14); treatment-naive and intended treatment duration of 72 weeks (n = 6).</p
    corecore